Mirum Pharmaceuticals, Inc. (MIRM)
| Market Cap | 6.04B +64.5% |
| Revenue (ttm) | 670.78M +42.2% |
| Net Income | -903.88M |
| EPS | -15.12 |
| Shares Out | 65.28M |
| PE Ratio | n/a |
| Forward PE | n/a |
| Dividend | n/a |
| Ex-Dividend Date | n/a |
| Volume | 498,219 |
| Open | 91.53 |
| Previous Close | 91.95 |
| Day's Range | 90.96 - 93.00 |
| 52-Week Range | 63.23 - 130.00 |
| Beta | 0.74 |
| Analysts | Strong Buy |
| Price Target | 157.71 (+70.52%) |
| Earnings Date | Nov 3, 2026 |
About MIRM
Mirum Pharmaceuticals, Inc., a biopharmaceutical company, focuses on the development and commercialization of novel therapies for debilitating rare and orphan diseases. Its lead product candidate is LIVMARLI (maralixibat), an orally administered and minimally absorbed ileal bile acid transporter (IBAT) inhibitor that is approved for the treatment of cholestatic pruritus in patients with Alagille syndrome in the United States and internationally. The company is also involved in the commercialization of Cholbam, a cholic acid capsule, which is ap... [Read more]
Financial Performance
In 2025, Mirum Pharmaceuticals's revenue was $521.31 million, an increase of 54.74% compared to the previous year's $336.89 million. Losses were -$23.36 million, -73.43% less than in 2024.
Financial StatementsAnalyst Summary
According to 12 analysts, the average rating for MIRM stock is "Strong Buy." The 12-month stock price target is $157.71, which is an increase of 70.52% from the latest price.
News
Mirum Pharmaceuticals Transcript: Jefferies Global Healthcare Conference
Four approved medicines support FY 2026 revenue guidance of $715Mā$720M, with cash flow positive status expected in 2027. Planned 2027 filings could lead to approvals and launches from late 2027 through 2028.
Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4).
Mirum Pharmaceuticals Transcript: Stifel 2026 Healthcare Conference 2026
2026 revenue guidance is $715M-$720M, with cash-flow-positive guidance for 2027 and significant contributions expected from ATEBRIOZ. Pipeline milestones include a brelovitug filing next year and volixibat data in PBC in Q1 2027.
Mirum Pharmaceuticals price target raised to $194 from $184 at Citi
Citi raised the firmās price target on Mirum Pharmaceuticals (MIRM) to $194 from $184 and keeps a Buy rating on the shares. The firm says the success of the AZURE-4ā¦
Mirum Pharmaceuticals reports primary endpoint met in AZURE-4 Phase 3 study
Mirum Pharmaceuticals (MIRM) announced that the primary endpoint was met in the Phase 3 AZURE-4 study evaluating brelovitug, an investigational fully human monoclonal antibody that binds to hepatitis ...
Mirum's liver infection drug lowers virus levels in second late-stage study
Mirum Pharmaceuticals said on Tuesday its experimental treatment for hepatitis delta, āa serious liver infection, led to āreduced virus and normal liver enzyme levels, meeting the main goal of a secon...
Mirum Pharmaceuticals Transcript: 8th Annual Wolfe Research Healthcare Conference
Five regulatory filings are expected in 2027, with multiple approvals targeted within 18 months. Growth spans LIVMARLI, biliary atresia, volixibat and HDV; brelovitugās BLA is on track for H1 2027, and positive cash flow is expected in 2027.
Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Announces Primary Endpoint Met in AZURE-4 Phase 3 Study and Highlights Long-Term Brelovitug Data Presented at AASLD.
Mirum Pharmaceuticals Slides: Corporate presentation
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 10, 2026.
GeneDx, Mirum launch sponsored testing programs
GeneDx (WGS) announced a collaboration with Mirum (MIRM) to offer no-cost exome testing for eligible patients across three sponsored testing programs: cholestasis, early-onset cataracts, and peroxisom...
GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing
GAITHERSBURG, Md.--(BUSINESS WIRE)--GeneDx and Mirum Pharmaceuticals Launch Sponsored Testing Programs to Help Patients Find Answers Through Comprehensive Genetic Testing.
Mirum Pharmaceuticals price target raised to $160 from $155 at Cantor Fitzgerald
Cantor Fitzgerald analyst Josh Schimmer raised the firmās price target on Mirum Pharmaceuticals (MIRM) to $160 from $155 and keeps an Overweight rating on the shares.
Mirum Pharmaceuticals price target raised to $202 from $200 at H.C. Wainwright
H.C. Wainwright analyst Swayampakula Ramakanth raised the firmās price target on Mirum Pharmaceuticals (MIRM) to $202 from $200 and keeps a Buy rating on the shares. The company reported āanotherā¦
Mirum Pharmaceuticals price target raised to $167 from $144 at Citizens
Citizens analyst Jonathan Wolleben raised the firmās price target on Mirum Pharmaceuticals (MIRM) to $167 from $144 and keeps an Outperform rating on the shares. Livmarli delivered another strong quar...
Mirum Pharmaceuticals Earnings Call Transcript: Q3 2026
Q3 net product sales reached $186M, lifting FY 2026 guidance to $715M-$720M. Commercial growth, ATEBRIOZās launch and multiple 2027 regulatory milestones underpin the next growth phase.
Mirum Pharmaceuticals Earnings release: Q3 2026
Mirum Pharmaceuticals released its Q3 2026 earnings on November 3, 2026, summarizing the period's financial results.
Mirum Pharmaceuticals Quarterly report: Q3 2026
Mirum Pharmaceuticals has published its Q3 2026 quarterly earnings report on November 3, 2026.
Mirum Pharmaceuticals raises FY26 revenue view to $715M-$720M, consensus $698.1M
The company guided $680M-$700M.
Mirum Pharmaceuticals reports Q3 EPS (87c), consensus (41c)
Reports Q3 revenue $185.7M, consensus $178.0M. āThe third quarter was an important period of execution for Mirum, with the approval and launch of ATEBRIOZ and positive Phase 3 results acrossā¦
Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Reports Third Quarter 2026 Financial Results and Provides Business Update.
Mirum Pharmaceuticals Slides: Corporate presentation
Mirum Pharmaceuticals has posted slides in relation to its latest quarterly earnings report, which was published on November 3, 2026.
Mirum Pharmaceuticals showcases momentum across rare liver disease portfolio
Mirum Pharmaceuticals (MIRM) announced that data from its rare liver disease portfolio will be presented at the American Association for the Study of Liver Diseasesā The Liver Meeting 2026, takingā¦
Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver MeetingĀ® 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals Showcases Momentum Across Rare Liver Disease Portfolio with New Data at AASLD's The Liver MeetingĀ® 2026.
Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026
FOSTER CITY, Calif.--(BUSINESS WIRE)--Mirum Pharmaceuticals to Announce Third Quarter 2026 Financial Results and Host Conference Call on November 3, 2026.
Mirum announces results from Cohort 2 of Progress study of Atebrioz
Mirum Pharmaceuticals (MIRM) announced positive results from Cohort 2 of the pivotal Progress study of Atebrioz, an oral activin receptor-like kinase 2 inhibitor, in pediatric patients aged 6 to lessā¦